This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2005 Feb;173(2):441.

doi: 10.1097/01.ju.0000148855.17830.97.

Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer

Takuya Yamagishi¹, Hiroji Uemura, Noboru Nakaigawa, Kazumi Noguchi, Yoshinobu Kubota

Affiliations

PMID: 15643197
DOI: 10.1097/01.ju.0000148855.17830.97

Case Reports

Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer

Takuya Yamagishi et al. J Urol. 2005 Feb.

. 2005 Feb;173(2):441.

doi: 10.1097/01.ju.0000148855.17830.97.

Authors

Takuya Yamagishi¹, Hiroji Uemura, Noboru Nakaigawa, Kazumi Noguchi, Yoshinobu Kubota

Affiliation

¹ Department of Urology, Yokohama City University School of Medicine, Yokohama, Japan.

PMID: 15643197
DOI: 10.1097/01.ju.0000148855.17830.97

No abstract available

PubMed Disclaimer

Similar articles

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y. Uemura H, et al. Int J Clin Oncol. 2005 Dec;10(6):405-10. doi: 10.1007/s10147-005-0520-y. Int J Clin Oncol. 2005. PMID: 16369744 Clinical Trial.
Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis B, Page SR. Mendis B, et al. Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. Expert Opin Pharmacother. 2009. PMID: 19563275 Review.
The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y. Soga N, et al. Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20. Jpn J Clin Oncol. 2012. PMID: 22438406
Hypertension after kidney transplantation: still a SECRET?
Lopau K, Wanner C. Lopau K, et al. Nephrol Dial Transplant. 2010 Mar;25(3):664-5. doi: 10.1093/ndt/gfp712. Epub 2009 Dec 29. Nephrol Dial Transplant. 2010. PMID: 20042402 No abstract available.
[The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H, Takagi H. Ohashi H, et al. Nihon Rinsho. 2005 Jun;63 Suppl 6:297-301. Nihon Rinsho. 2005. PMID: 15999723 Review. Japanese. No abstract available.

See all similar articles

Cited by

Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells.
Piastowska-Ciesielska AW, Kozłowski M, Wagner W, Domińska K, Ochędalski T. Piastowska-Ciesielska AW, et al. Arch Med Sci. 2013 Aug 30;9(4):739-44. doi: 10.5114/aoms.2012.30955. Epub 2012 Oct 8. Arch Med Sci. 2013. PMID: 24049538 Free PMC article.
Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor.
Ito Y, Naiki-Ito A, Kato H, Suzuki S, Kuno T, Ishiguro Y, Takahashi S, Uemura H. Ito Y, et al. Oncotarget. 2018 Feb 14;9(17):13859-13869. doi: 10.18632/oncotarget.24492. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568400 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information